On Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion. Operational growth was 6.6%, and adjusted operational growth was 6.5%. The adjusted operational growth excluding COVID-19 Vaccine was 7.1%. Also Read: Johnson & Johnson Faces MedTech Challenges But Is ‘On Track’ To Meet 2024 Guidance: Goldman Sachs. Innovative Medicine sales increased to $14.49 billion, up 5.5% (+8% adjusted operational). Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Tremfya ...